Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-10

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase 1 study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult healthy volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Following A Single Dose Of PF-04995274 In Healthy Adult Volunteers

NCT01091272

Healthy

COMPLETED PHASE1

A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers

NCT01897142

Healthy

COMPLETED PHASE1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy Subjects

NCT03217604

Healthy Volunteers

COMPLETED PHASE1

First-in-Human Study of PF-04958242 in Healthy Volunteers

NCT01159483

Healthy Volunteer

COMPLETED PHASE1

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

NCT02228395

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Enrolled participants in this study will receive a single dose of DISC-0974 or a placebo. Samples will be collected to measure how DISC-0974 is processed by the body and how the body responds when exposed to DISC-0974. Participants will receive a single study drug dose on Day 1; and follow-up for 10 weeks (71 days). If an undetectable DISC-0974 blood concentration is observed, the duration of follow-up will be shortened to 7 days thereafter, as feasible.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Volunteer: Single Ascending Dose of DISC-0974

Single Intravenous (IV) or Subcutaneous (SC) ascending dose in healthy volunteers

Group Type EXPERIMENTAL

DISC-0974

Intervention Type DRUG

DISC-0974 is administered (IV infusion or Subcutaneous Injection) as a single dose

Healthy Volunteer: Single Ascending Dose of Placebo

Single Intravenous (IV) or Subcutaneous (SC) ascending dose in healthy volunteers

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DISC-0974

DISC-0974 is administered (IV infusion or Subcutaneous Injection) as a single dose

Intervention Type DRUG

Placebo

Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female (HV only) adults aged 18 to 65 years, inclusive at the time of consent.
* Body weight ≥50 kg and body mass index (BMI) between 18 and 33, inclusive, at Screening.
* Systolic blood pressure ≤140 mmHg and diastolic blood pressure ≤90 at Screening.
* No clinically significant abnormalities as determined by medical history, by results of physical examination, vital signs, ECG and lab tests at Screening.
* QTcF \<450 msec at Screening.
* Estimated glomerular filtration rate \>60 mL/min/1.73m2 based on the 4 parameter MDRD (Modification of Diet in Renal Disease) equation at Screening
* TSAT ≤30% at Screening, as determined in a fasting morning blood sample (06:00 to 11:00 hours).
* Hematologic parameters (red blood cell count \[RBC\], hemoglobin, hematocrit, platelet count, mean corpuscular volume, mean corpuscular hemoglobin concentration), serum iron, and TIBC within normal range and serum ferritin (within normal range and ≥30 ng/mL) at Screening.
* If a male with female sexual partner(s) of childbearing potential, must agree to use acceptable methods of birth control during the study and through the End of Study (EOS) visit
* If female, postmenopausal, as defined with at least 12 months natural, spontaneous amenorrhea, or at least 6 weeks following surgical menopause
* Able to understand and provide written informed consent and comply with protocol requirements

Exclusion Criteria

* History of anemia or hematologic disorder within 1 year of Screening
* History of splenectomy
* Diagnosis or first-degree relative with a diagnosis of hemochromatosis
* History of diabetes, cardiovascular, hepatic, renal, or malabsorptive disease
* Vegan or iron-deficient diet within 3 months of Screening
* Blood transfusion within 1 year of Screening
* Whole blood donation within 6 months of Screening or plasma donation within 30 days of Screening.
* A history of alcohol or illicit drug use disorder within 3 years of Screening, as assessed by the Investigator
* Use of any tobacco- and/or nicotine-containing containing products, including e-cigarettes, vaping products, and nicotine replacement products, within 3 months of Screening
* Use of multivitamin or iron supplements within 30 days prior to Screening
* ALT or aspartate aminotransferase (AST) level above the normal range at Screening
* Positive urine pregnancy test at Screening or Baseline (Day -1).
* Positive serologic test for Hepatitis B surface antigen, Hepatitis C antibody, or human immunodeficiency virus (HIV) at Screening.
* Positive urine screen for drugs of abuse or alcohol test on admission to the study center
* Use of any systemic prescription medication within 14 days of Screening, non-iron containing dietary supplements, or non-prescription drugs within 7 days of dosing.
* History of a major surgical procedure within 60 days of Screening or planned surgical procedure within 90 days of dosing.
* A history or known allergic reaction to any investigational product excipients or history of anaphylaxis to any food or drug.
* History or presence or any illness that, in the opinion of the Investigator, would interfere with the ability to provide informed consent or comply with study instructions.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes